The narrowly approved equity plan expansion (57.8% For) and officer exculpation amendment are governance items with no immediate earnings impact. Monitor future 10-Q filings for actual equity grant activity under the expanded plan, as the 3.8M-share reserve is material relative to current share count (~14.6% potential dilution). No stock-moving catalysts in this filing.
Price Chart
Executive Summary
Precision BioSciences held its 2026 annual meeting on May 21, 2026, with roughly 86% of shares represented. Shareholders narrowly approved a 3,800,000-share increase to the 2019 Incentive Award Plan (11.2M for, 8.1M against), elected directors Melinda Brown and Geno Germano, ratified Deloitte & Touche as auditor, approved say-on-pay, and adopted an officer exculpation amendment to the certificate of incorporation. The filing is an administrative post-meeting report with no financial performance data; the equity plan expansion enables future equity grants but also represents potential dilution.
Key Facts
- Annual meeting held May 21, 2026; 22,304,867 shares (86% of outstanding) were represented.
- Shareholders approved a 3,800,000-share increase to the 2019 Incentive Award Plan with 11,170,635 votes For, 8,145,992 Against — a relatively narrow margin of 57.8% For.
- Melinda Brown (14,348,888 For) and Geno Germano (14,288,270 For) were elected as Class I directors to serve until the 2029 annual meeting.
- Deloitte & Touche LLP was ratified as independent auditor for FY2026 with 22,198,597 For.
- Advisory say-on-pay was approved (18,696,193 For, 612,836 Against).
- Stockholders approved an amendment to the certificate of incorporation (17,909,703 For) to provide officer exculpation as permitted under Delaware law, filed with the Secretary of State on May 22, 2026.
- No departures of directors or officers were reported; no CEO/CFO changes occurred.
Financial Impact
No financial data in this filing. The equity plan increase adds up to 3,800,000 new common shares available for issuance, representing approximately 14.6% dilution relative to the roughly 26M shares outstanding (based on 86% representation of 22.3M shares implying ~25.9M total outstanding on record date). Actual dilutive impact depends on future grant activity.
Risk Factors
- Potential future dilution from grants under the expanded equity plan (~3.8M new shares authorized).
- Relatively high 'Against' vote on equity plan (42.2% Against) signals some institutional dissatisfaction with dilution; could foreshadow future proxy challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038220 |
| Document: dtil-20260521.htm | 0001628280-26-038220 |
| Document: dtil-proposedamendmenttoar.htm | 0001628280-26-038220 |
| Document: 0001628280-26-038220-index-headers.html | 0001628280-26-038220 |
| Document: 0001628280-26-038220-index.html | 0001628280-26-038220 |
| Document: 0001628280-26-038220.txt | 0001628280-26-038220 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $7.19 $6.36 | ▼ −11.54% | ▼ −10.82% | $6.75 (−6.12%) |
Aug 24, 2026 9w ago | 8-K | $8.45 $8.55 | ▲ +1.18% | ▲ +0.86% | $6.75 (−20.12%) |
Aug 6, 2026 11w ago | 8-K | $7.42 $7.49 | ▲ +0.94% | ▲ +0.33% | $6.75 (−9.03%) |
Jul 27, 2026 13w ago | 8-K | $7.25 $7.17 | ▼ −1.10% | ▼ −1.34% | $6.75 (−6.90%) |
Jul 1, 2026 16w ago | 8-K | $7.88 $8.18 | ▲ +3.81% | ▲ +3.94% | $6.75 (−14.34%) |
Jun 16, 2026 18w ago | 8-K | $6.50 $6.81 | ▲ +4.77% | ▲ +3.99% | $6.75 (+3.85%) |
May 27, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.75 (−11.07%) |
May 26, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.75 (−11.07%) |
May 5, 2026 25w ago | 8-K | $7.45 $7.52 | ▲ +0.94% | ▼ −0.45% | $6.75 (−9.40%) |
Apr 8, 2026 28w ago | DEFA14A | $5.99 $6.61 | ▲ +10.35% | ▲ +9.78% | $6.75 (+12.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers